• In late April 2026, Medtronic reported progress across its Affera cardiac arrhythmia portfolio, including promising ventricular tachycardia and atrial fibrillation data, an FDA Breakthrough Device Designation for the Sphere-9 catheter in VT, and new global trial enrollments, while also securing CE Mark for its Stealth AXiS surgical system for spine and cranial procedures.
• These regulatory wins and early clinical results highlight Medtronic’s push into next-generation arrhythmia ablation and integrated surgical robotics, potentially strengthening its position in complex cardiovascular and neurosurgical care.
• We’ll now explore how the FDA Breakthrough Device status for Sphere-9 might influence Medtronic’s investment narrative and long-term growth assumptions.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Medtronic Investment Narrative Recap

To own Medtronic, I think you need to believe its broad cardiovascular and surgical technology portfolio can steadily compound earnings while it works through margin pressure and uneven growth in areas like Diabetes and MedSurg. The latest Affera arrhythmia data and Stealth AXiS approvals reinforce the innovation story, but do not materially change the near term focus on execution in major product ramp ups and the Diabetes separation, which remain the key catalyst and the biggest risk right now.

The FDA Breakthrough Device Designation for the Sphere-9 catheter in ventricular tachycardia stands out here because it directly ties into Medtronic’s cardiac ablation systems ramp, a central piece of the growth narrative. By potentially accelerating the regulatory path and broadening Affera’s clinical profile, this announcement sits right at the intersection of Medtronic’s innovation pipeline and the execution risks around bringing complex CAS and pulsed field ablation platforms to market at scale.

Yet, while these advances are encouraging, investors should still be aware of the execution risk around Medtronic’s large new product ramp ups, where...

Medtronic's narrative projects $40.8 billion revenue and $6.5 billion earnings by 2029. This requires 4.8% yearly revenue growth and about a $1.9 billion earnings increase from $4.6 billion today.

Uncover how Medtronic's forecasts yield a $109.08 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Eleven members of the Simply Wall St Community see Medtronic’s fair value between US$87.94 and US$109.08, highlighting a wide spread of views. Set this against the execution risk in Medtronic’s major new product rollouts and it becomes even more important to weigh several perspectives on how reliably innovation could translate into future performance.

Explore 11 other fair value estimates on Medtronic - why the stock might be worth just $87.94!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Medtronic research is our analysis highlighting 6 key rewards that could impact your investment decision.
• Our free Medtronic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Medtronic's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.